Latest Commercialisation News

Environmental Clean Technologies Limited (ECT) is set to acquire exclusive rights to Rice University’s innovative Flash Joule Heating technology, promising a breakthrough in PFAS soil remediation. The company also announces a $3 million capital raise to accelerate development and commercialisation.

Latrobe Magnesium Limited has successfully commenced production of Magnesium Oxide at its Hazelwood North Demonstration Plant, marking a significant operational milestone. The company is advancing towards steady-state output and exploring by-product commercialisation.

Strategic Elements Ltd has successfully fabricated over 2,000 Energy Ink™ prototype cells in a commercial setting, marking a pivotal step toward global collaboration and product development. This breakthrough validates the reproducibility of their moisture-powered printable ink technology at scale.

Green Critical Minerals has locked in a $5.2 million underwriting agreement to support the exercise of its expiring options, reinforcing its commercialisation strategy for innovative VHD graphite technology.

Zeotech Limited has signed a non-binding MOU with construction giant Laing O’Rourke to trial its innovative low-carbon AusPozz™ metakaolin in live infrastructure projects, aiming to validate and accelerate the commercial adoption of sustainable building materials.

Race Oncology has secured Investigational New Drug approval from South Korea’s regulatory authority, enabling Phase 1 clinical trials of RC220 in combination with doxorubicin for solid tumour patients across four Korean sites.

EMVision Medical Devices has initiated a unique pre-hospital study in Melbourne to test its First Responder Brain Scanner within one of the world’s few Mobile Stroke Units, aiming to enhance stroke diagnosis and accelerate commercialisation.

Micro-X Ltd has secured a $4.4 million Australian Government grant to develop and trial a portable Head CT scanner designed for standard ambulances, aiming to transform emergency stroke care with faster diagnosis and treatment.

Bio-Gene Technology’s novel acaricide Flavocide demonstrated over 90% mortality against Lyme disease-carrying ticks in lab tests presented by Purdue University, highlighting its potential in public health applications.

Algorae Pharmaceuticals has secured an exclusive licensing agreement with Sakar Healthcare to introduce five generic oncology medicines in Australia and New Zealand, marking its first commercial foray in the region.

Clover Corporation posted a robust 38% revenue increase to $86 million in FY25, driven by product innovation and operational gains, while declaring a final dividend. The company’s cautious outlook for FY26 reflects ongoing regulatory and production challenges.

Hazer Group has been granted a pivotal patent in Singapore for its proprietary graphite morphology process, reinforcing its foothold in Southeast Asia's clean energy and advanced manufacturing markets.